NIVABUPA - Investment Analysis: Buy Signal or Bull Trap?
Back to ListInvestment Rating: 2.7
| Stock Code | NIVABUPA | Market Cap | 12,977 Cr. | Current Price | 69.9 ₹ | High / Low | 95.2 ₹ |
| Book Value | 20.6 ₹ | Dividend Yield | 0.00 % | ROCE | 7.45 % | ROE | 8.18 % |
| Face Value | 10.0 ₹ | DMA 50 | 74.7 ₹ | DMA 200 | 77.4 ₹ | Chg in FII Hold | -0.41 % |
| Chg in DII Hold | 0.73 % | PAT Qtr | -87.6 Cr. | PAT Prev Qtr | -35.3 Cr. | RSI | 33.6 |
| MACD | -1.54 | Volume | 9,81,925 | Avg Vol 1Wk | 56,34,775 | Low price | 61.0 ₹ |
| High price | 95.2 ₹ | Debt to equity | 0.07 | 52w Index | 26.0 % | Qtr Profit Var | -762 % |
| EPS | -0.03 ₹ | Industry PE | 32.6 |
📊 Niva Bupa (NIVABUPA) shows weak fundamentals with low ROE (8.18%) and ROCE (7.45%), alongside consistent losses (PAT -87.6 Cr. vs. -35.3 Cr. previous quarter). The absence of a P/E and PEG ratio highlights poor profitability and growth prospects. Dividend yield is 0%, offering no income support. Technical indicators (RSI 33.6, MACD -1.54) show weakness, with the stock trading below both 50 DMA (74.7 ₹) and 200 DMA (77.4 ₹). The ideal entry zone for long-term investors would be ₹62–₹68, closer to its recent low of ₹61. If already holding, investors should adopt a cautious stance, with exits near ₹90–₹95 to limit risk exposure.
✅ Positive
- Debt-to-equity ratio of 0.07 indicates low leverage.
- DII holding increased (+0.73%), showing domestic institutional support.
- Book value of ₹20.6 provides some valuation cushion.
⚠️ Limitation
- Negative EPS (-0.03 ₹) reflects continued losses.
- Low ROE (8.18%) and ROCE (7.45%) compared to peers.
- No dividend yield (0%) reduces attractiveness for income investors.
- Stock trading below key moving averages (DMA 50 & DMA 200).
📉 Company Negative News
- Quarterly PAT worsened from -35.3 Cr. to -87.6 Cr. (-762% variation).
- FII holding reduced (-0.41%), showing weaker foreign investor confidence.
- Technical weakness: RSI near oversold zone (33.6), MACD negative (-1.54).
📈 Company Positive News
- DII holding increased (+0.73%), showing domestic institutional support.
- Low debt-to-equity ratio provides financial resilience.
🏭 Industry
- Industry P/E at 32.6 suggests peers are profitable, unlike Niva Bupa.
- Insurance sector expected to benefit from rising healthcare awareness and government initiatives, but company-specific weakness limits upside.
🔎 Conclusion
Niva Bupa is currently a weak candidate for long-term investment due to negative profitability metrics and lack of dividend support. Long-term investors should only consider accumulation in the ₹62–₹68 zone for speculative positioning. Existing holders should adopt a cautious 2–3 year horizon, with exits near ₹90–₹95 to reduce risk. While sector tailwinds may provide some support, company-specific fundamentals remain unfavorable.